CUSIP 10806X102 · who reports it, how much, and how much it matters to them
46 of the 720 hedge fund managers we track reported shares of BridgeBio Pharma, Inc. (Nasdaq: BBIO) on Form 13F for 30 June 2026. Between them they reported USD 4.5bn. The largest position belongs to Kohlberg Kravis Roberts & Co., at USD 988m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Kohlberg Kravis Roberts & Co.34 funds on PPLI.com | USD 988m | 17.3% |
| 2 | Farallon Capital Management56 funds on PPLI.com | USD 800m | 3.7% |
| 3 | Viking Global Investors4 funds on PPLI.com | USD 741m | 2.1% |
| 4 | Two Sigma Investments35 funds on PPLI.com | USD 352m | 0.3% |
| 5 | Citadel Advisors32 funds on PPLI.com | USD 280m | 0.0% |
| 6 | D. E. Shaw & Co.15 funds on PPLI.com | USD 271m | 0.1% |
| 7 | Adage Capital Management1 fund on PPLI.com | USD 168m | 0.2% |
| 8 | Polar Capital LLP26 funds on PPLI.com | USD 154m | 0.4% |
| 9 | POINT72 Asset Management17 funds on PPLI.com | USD 114m | 0.1% |
| 10 | Balyasny Asset Management25 funds on PPLI.com | USD 92m | 0.1% |
| 11 | Squarepoint Ops7 funds on PPLI.com | USD 89m | 0.1% |
| 12 | Renaissance Technologies13 funds on PPLI.com | USD 64m | 0.1% |
| 13 | Summit Partners Public Asset Management14 funds on PPLI.com | USD 46m | 0.8% |
| 14 | Cormorant Asset Management1 fund on PPLI.com | USD 41m | 2.1% |
| 15 | Millennium Management6 funds on PPLI.com | USD 36m | 0.0% |
| 16 | Bridgewater Associates45 funds on PPLI.com | USD 33m | 0.1% |
| 17 | Boone Capital Management1 fund on PPLI.com | USD 25m | 5.9% |
| 18 | Weiss Asset Management5 funds on PPLI.com | USD 24m | 0.2% |
| 19 | Marshall Wace LLP84 funds on PPLI.com | USD 21m | 0.0% |
| 20 | PFM Health Sciences3 funds on PPLI.com | USD 19m | 1.6% |
| 21 | Sphera Funds Management1 fund on PPLI.com | USD 18m | 2.4% |
| 22 | Exoduspoint Capital Management7 funds on PPLI.com | USD 17m | 0.1% |
| 23 | Brevan Howard Capital Management39 funds on PPLI.com | USD 12m | 0.1% |
| 24 | Rock Springs Capital Management2 funds on PPLI.com | USD 11m | 0.5% |
| 25 | Voleon Capital Management13 funds on PPLI.com | USD 10m | 0.2% |
| 26 | Tudor Investment Corporation10 funds on PPLI.com | USD 5.7m | 0.0% |
| 27 | LMR Partners2 funds on PPLI.com | USD 4m | 0.0% |
| 28 | Platinum Investment Management11 funds on PPLI.com | USD 3m | 0.7% |
| 29 | Engineers Gate Manager1 fund on PPLI.com | USD 2.8m | 0.0% |
| 30 | Campbell & Company Investment Adviser8 funds on PPLI.com | USD 2.6m | 0.1% |
| 31 | Hudson Bay Capital Management8 funds on PPLI.com | USD 1.9m | 0.0% |
| 32 | Exome Asset Management2 funds on PPLI.com | USD 1.4m | 0.8% |
| 33 | Boothbay Fund Management2 funds on PPLI.com | USD 1.2m | 0.0% |
| 34 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 995,000 | 0.0% |
| 35 | HighVista Strategies27 funds on PPLI.com | USD 980,000 | 0.2% |
| 36 | Diametric Capital2 funds on PPLI.com | USD 692,000 | 0.1% |
| 37 | The Quarry1 fund on PPLI.com | USD 521,000 | 0.0% |
| 38 | CIBC Asset Management69 funds on PPLI.com | USD 447,000 | 0.0% |
| 39 | Lion Point Capital1 fund on PPLI.com | USD 372,000 | 1.8% |
| 40 | Gabelli & Company Investment Advisers17 funds on PPLI.com | USD 335,000 | 0.0% |
| 41 | Fulcrum Asset Management LLP7 funds on PPLI.com | USD 321,000 | 0.0% |
| 42 | Magnetar Financial93 funds on PPLI.com | USD 279,000 | 0.0% |
| 43 | Bayforest Capital1 fund on PPLI.com | USD 200,000 | 0.2% |
| 44 | Freestone Grove Partners1 fund on PPLI.com | USD 188,000 | 0.0% |
| 45 | Walleye Capital8 funds on PPLI.com | USD 114,000 | 0.0% |
| 46 | Persistent Asset Partners10 funds on PPLI.com | USD 39,176 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Kohlberg Kravis Roberts & Co. | USD 988m | 17.3% |
| 2 | Boone Capital Management | USD 25m | 5.9% |
| 3 | Farallon Capital Management | USD 800m | 3.7% |
| 4 | Sphera Funds Management | USD 18m | 2.4% |
| 5 | Viking Global Investors | USD 741m | 2.1% |
| 6 | Cormorant Asset Management | USD 41m | 2.1% |
| 7 | Lion Point Capital | USD 372,000 | 1.8% |
| 8 | PFM Health Sciences | USD 19m | 1.6% |
| 9 | Exome Asset Management | USD 1.4m | 0.8% |
| 10 | Summit Partners Public Asset Management | USD 46m | 0.8% |
BridgeBio Pharma, Inc. trades under the symbol BBIO on the Nasdaq. Its CUSIP, the code used on Form 13F, is 10806X102.
46 of the 720 hedge fund managers PPLI.com tracks reported BridgeBio Pharma, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Kohlberg Kravis Roberts & Co. (USD 988m), Farallon Capital Management (USD 800m), Viking Global Investors (USD 741m), Two Sigma Investments (USD 352m) and Citadel Advisors (USD 280m).
46 managers in our coverage reported it, and between them they run 797 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Kohlberg Kravis Roberts & Co., where the position was 17.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with BridgeBio Pharma, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.